Testing a new antibody treatment for anti-NMDAR brain disease
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a new medicine (ART5803) in people whose immune system attacks a brain receptor called NMDAR, causing encephalitis (brain swelling) or psychiatric symptoms. It aims to see if the medicine can reduce symptoms like confusion, memory problems, or psychosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed anti-NMDAR antibody in your spinal fluid or blood (a special test).
- You must be between 18 and 65 years old.
- Your symptoms must have lasted at least 4 months (for certain groups).
- You cannot have other serious brain conditions like multiple sclerosis.
- You must be willing to use birth control if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new lab test that may help doctors more accurately diagnose GABABR antibody encephalitis, a type of brain inflammation. The test looks for certain antibodies in your blood or spinal fluid.
This research study looks for new markers in the blood of people with autoimmune encephalitis (a condition where the immune system attacks the brain). It aims to better understand what causes the disease and find new ways to diagnose it.
This Phase 2 study tests inebilizumab in people with NMDA receptor encephalitis, an immune-related brain condition. It looks to see if adding this treatment after starting steroids (and possibly other first treatments) improves recovery and safety.
This study tests a natural bile-derived medicine (Calcus Bovis Sativus) to see if it can help adults with new or recent brain inflammation (encephalitis). It focuses on people whose encephalitis is caused by the immune system or a virus, and who have not fully recovered.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a drug called efgartigimod, which may help people with anti-NMDA receptor encephalitis, a condition where the immune system attacks the brain. The study aims to see if it can improve symptoms when added to standard steroid treatment.
Hear when a new Autoimmune Encephalitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.